Literature DB >> 21217771

4-1BB signaling beyond T cells.

Dass S Vinay1, Byoung S Kwon.   

Abstract

Originally discovered as a T cell-activating molecule, 4-1BB (CD137) is now also recognized as an activator of non-T cells, thus imparting a new dimension to its potential in vivo effects. 4-1BB expression is seen on a variety of non-T cells including activated dendritic cells (DCs), monocytes, neutrophils, B cells and natural killer (NK) cells, and promotes their individual effector functions. The T cell- and non-T cell-activating ability of 4-1BB may be the basis of its powerful anti-cancer, anti-autoimmune and anti-viral effects. Here we discuss the consequence and importance of 4-1BB signaling in non-T cells. We consider its effects on immune regulation, and the distinct and/or overlapping pathways involved in these responses, as well as possible therapeutic applications.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21217771      PMCID: PMC4002439          DOI: 10.1038/cmi.2010.82

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  35 in total

1.  TGFbeta protein processing and activity through TCR triggering of primary CD8+ T regulatory cells.

Authors:  Antoine Ménoret; Lara M Myers; Seung-Joo Lee; Robert S Mittler; Robert J Rossi; Anthony T Vella
Journal:  J Immunol       Date:  2006-11-01       Impact factor: 5.422

2.  Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice.

Authors:  Liguo Niu; Simona Strahotin; Becker Hewes; Benyue Zhang; Yuanyuan Zhang; David Archer; Trent Spencer; Dirck Dillehay; Byoung Kwon; Lieping Chen; Anthony T Vella; Robert S Mittler
Journal:  J Immunol       Date:  2007-04-01       Impact factor: 5.422

Review 3.  B-cell targeting in rheumatoid arthritis and other autoimmune diseases.

Authors:  Jonathan C W Edwards; Geraldine Cambridge
Journal:  Nat Rev Immunol       Date:  2006-05       Impact factor: 53.106

4.  4-1BB-mediated amelioration of experimental autoimmune uveoretinitis is caused by indoleamine 2,3-dioxygenase-dependent mechanisms.

Authors:  Beom K Choi; Tatsuhiko Asai; Dass S Vinay; Young H Kim; Byoung S Kwon
Journal:  Cytokine       Date:  2006-08-08       Impact factor: 3.861

5.  Amelioration of mercury-induced autoimmunity by 4-1BB.

Authors:  Dass S Vinay; Jung D Kim; Byoung S Kwon
Journal:  J Immunol       Date:  2006-10-15       Impact factor: 5.422

6.  Stimulation of the molecule 4-1BB enhances host defense against Listeria monocytogenes infection in mice by inducing rapid infiltration and activation of neutrophils and monocytes.

Authors:  Sang-Chul Lee; Seong-A Ju; Boo-Hee Sung; Sook-Kyoung Heo; Hong Rae Cho; Eun A Lee; Jung Dae Kim; In Hee Lee; Sang-Min Park; Quang Tam Nguyen; Jae-Hee Suh; Byung-Sam Kim
Journal:  Infect Immun       Date:  2009-02-23       Impact factor: 3.441

7.  CD137 promotes proliferation and survival of human B cells.

Authors:  Xiaoyu Zhang; Caroline J Voskens; Michelle Sallin; Amudhan Maniar; Carolina L Montes; Yue Zhang; Wei Lin; Guoyan Li; Erin Burch; Ming Tan; Ronna Hertzano; Andrei I Chapoval; Koji Tamada; Brian R Gastman; Dan H Schulze; Scott E Strome
Journal:  J Immunol       Date:  2009-12-11       Impact factor: 5.422

8.  4-1BB functions as a survival factor in dendritic cells.

Authors:  Beom K Choi; Young H Kim; Patrick M Kwon; Sang C Lee; Sang W Kang; Moon S Kim; Myoung J Lee; Byoung S Kwon
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

Review 9.  Blood monocytes: development, heterogeneity, and relationship with dendritic cells.

Authors:  Cedric Auffray; Michael H Sieweke; Frederic Geissmann
Journal:  Annu Rev Immunol       Date:  2009       Impact factor: 28.527

10.  Identification of regulatory functions for 4-1BB and 4-1BBL in myelopoiesis and the development of dendritic cells.

Authors:  Seung-Woo Lee; Yunji Park; Takanori So; Byoung S Kwon; Hilde Cheroutre; Robert S Mittler; Michael Croft
Journal:  Nat Immunol       Date:  2008-07-06       Impact factor: 25.606

View more
  58 in total

Review 1.  Next generation immune-checkpoints for cancer therapy.

Authors:  Chiara Donini; Lorenzo D'Ambrosio; Giovanni Grignani; Massimo Aglietta; Dario Sangiolo
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

Review 2.  Co-stimulatory and co-inhibitory pathways in cancer immunotherapy.

Authors:  Rachel E O'Neill; Xuefang Cao
Journal:  Adv Cancer Res       Date:  2019-04-17       Impact factor: 6.242

3.  Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy.

Authors:  Christina Claus; Claudia Ferrara; Wei Xu; Johannes Sam; Sabine Lang; Franziska Uhlenbrock; Rosmarie Albrecht; Sylvia Herter; Ramona Schlenker; Tamara Hüsser; Sarah Diggelmann; John Challier; Ekkehard Mössner; Ralf J Hosse; Thomas Hofer; Peter Brünker; Catherine Joseph; Jörg Benz; Philippe Ringler; Henning Stahlberg; Matthias Lauer; Mario Perro; Stanford Chen; Christine Küttel; Preethi L Bhavani Mohan; Valeria Nicolini; Martina Carola Birk; Amandine Ongaro; Christophe Prince; Reto Gianotti; Gregory Dugan; Christopher T Whitlow; Kiran Kumar Solingapuram Sai; David L Caudell; Armando G Burgos-Rodriguez; J Mark Cline; Michael Hettich; Maurizio Ceppi; Anna Maria Giusti; Flavio Crameri; Wouter Driessen; Peter N Morcos; Anne Freimoser-Grundschober; Victor Levitsky; Maria Amann; Sandra Grau-Richards; Thomas von Hirschheydt; Stella Tournaviti; Michael Mølhøj; Tanja Fauti; Viola Heinzelmann-Schwarz; Volker Teichgräber; Sara Colombetti; Marina Bacac; Alfred Zippelius; Christian Klein; Pablo Umaña
Journal:  Sci Transl Med       Date:  2019-06-12       Impact factor: 17.956

4.  Targeting 4-1BB costimulation to the tumor stroma with bispecific aptamer conjugates enhances the therapeutic index of tumor immunotherapy.

Authors:  Brett Schrand; Alexey Berezhnoy; Randall Brenneman; Anthony Williams; Agata Levay; Ling-Yuan Kong; Ganesh Rao; Shouhao Zhou; Amy B Heimberger; Eli Gilboa
Journal:  Cancer Immunol Res       Date:  2014-06-17       Impact factor: 11.151

5.  Aptamer-targeted inhibition of mTOR in T cells enhances antitumor immunity.

Authors:  Alexey Berezhnoy; Iris Castro; Agata Levay; Thomas R Malek; Eli Gilboa
Journal:  J Clin Invest       Date:  2014-01       Impact factor: 14.808

6.  Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production.

Authors:  Michelle K Gleason; Michael R Verneris; Deborah A Todhunter; Bin Zhang; Valarie McCullar; Sophia X Zhou; Angela Panoskaltsis-Mortari; Louis M Weiner; Daniel A Vallera; Jeffrey S Miller
Journal:  Mol Cancer Ther       Date:  2012-10-17       Impact factor: 6.261

7.  4-1BB signaling activates glucose and fatty acid metabolism to enhance CD8+ T cell proliferation.

Authors:  Beom K Choi; Do Y Lee; Don G Lee; Young H Kim; Seon-Hee Kim; Ho S Oh; Chungyong Han; Byoung S Kwon
Journal:  Cell Mol Immunol       Date:  2016-03-14       Impact factor: 11.530

Review 8.  Novel antibodies targeting immune regulatory checkpoints for cancer therapy.

Authors:  Chern Siang Lee; Mark Cragg; Martin Glennie; Peter Johnson
Journal:  Br J Clin Pharmacol       Date:  2013-08       Impact factor: 4.335

Review 9.  Advances in targeting cell surface signalling molecules for immune modulation.

Authors:  Sheng Yao; Yuwen Zhu; Lieping Chen
Journal:  Nat Rev Drug Discov       Date:  2013-02       Impact factor: 84.694

10.  Accumulation of 4-1BBL+ B cells in the elderly induces the generation of granzyme-B+ CD8+ T cells with potential antitumor activity.

Authors:  Catalina Lee-Chang; Monica Bodogai; Kanako Moritoh; Purevdorj B Olkhanud; Andrew C Chan; Michael Croft; Julie A Mattison; Peter Johannes Holst; Ronald E Gress; Luigi Ferrucci; Fran Hakim; Arya Biragyn
Journal:  Blood       Date:  2014-07-18       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.